15/04/2025 09:25
EQS-News: More Impact AG: Subsidiary BG Braingate Technology receives Notice of Allowance from the US Patent and Trademark Office for innovative technology
INFORMATION REGLEMENTEE

EQS-News: More Impact AG / Key word(s): Patent
More Impact AG: Subsidiary BG Braingate Technology receives Notice of Allowance from the US Patent and Trademark Office for innovative technology

15.04.2025 / 09:25 CET/CEST
The issuer is solely responsible for the content of this announcement.



PRESS RELEASE


More Impact AG: Subsidiary BG Braingate Technology receives Notice of Allowance from the US Patent and Trademark Office for innovative technology


Frankfurt am Main, April 15, 2025 – More Impact AG (ISIN: DE000A1PG979, “More Impact”), a listed high-tech medical hub, announces that its subsidiary BG Braingate Technology GmbH (“Braingate Technology”) has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for another of its technological innovations.


This means that the issuance of the patent by the US authorities is binding and absured. An important milestone for the international marketing of products based on the patented device and a special extraction process has thus been reached.


The patent application relates to an innovative device and a method for the efficient, selective and gentle extraction of one or more components from biological materials, in particular cannabinoids such as the medically used CBD. The biological components obtained by the patented process can be processed accordingly and administered either via the medical inhaler or via the needleless syringe, depending on the medical indication.


Dr. Karsten Behlke, Managing Director of BG Braingate Technology: “The pending issuance of the US patent is an important milestone for our international protection strategy and the commercial exploitation of our technology in the fast-growing market for plant-based active substances.”


Dr. Gerald Schüssel, CEO of More Impact: “With the US patent granted in the near future, the high level of technological innovation in our portfolio companies is once again underpinned on an international scale.”


With the forthcoming patent grant, More Impact and Braingate Technology are expanding their leading technological position in the field of innovative extraction processes.


The forthcoming patent issuance complements the existing patent families and underpins the high-tech medical hub's claim to technological and innovative leadership.


About More Impact AG
More Impact AG is a listed high-tech medical hub that specializes in the development and support of innovative companies in the medical field. With a focus on securing patents and commercializing product innovations, More Impact contributes to making cutting-edge MedTech technologies accessible to a broad part of the population and sustainably improving global healthcare. Strategic acquisitions and divestitures of companies, divisions or individual patents round off the business model.


Contact – Investor & Media Relations
edicto GmbH
Axel Mühlhaus / Svenja Liebig
+49 69 90550 5-50
moreimpact@edicto.de


 




15.04.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com



Language: English
Company: More Impact AG
Mörfelder Landstraße 277 b
60598 Frankfurt
Germany
Phone: +49 69 38076661
E-mail: info@moreimpactag.de
Internet: https://moreimpactag.de
ISIN: DE000A1PG979, DE000A40ZTM3
WKN: A1PG97
Listed: Regulated Unofficial Market in Dusseldorf
EQS News ID: 2118140

 
End of News EQS News Service

2118140  15.04.2025 CET/CEST

















EQS-News: More Impact AG


/ Key word(s): Patent






More Impact AG: Subsidiary BG Braingate Technology receives Notice of Allowance from the US Patent and Trademark Office for innovative technology








15.04.2025 / 09:25 CET/CEST




The issuer is solely responsible for the content of this announcement.




PRESS RELEASE



More Impact AG: Subsidiary BG Braingate Technology receives Notice of Allowance from the US Patent and Trademark Office for innovative technology



Frankfurt am Main, April 15, 2025 – More Impact AG (ISIN: DE000A1PG979, “More Impact”), a listed high-tech medical hub, announces that its subsidiary BG Braingate Technology GmbH (“Braingate Technology”) has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for another of its technological innovations.



This means that the issuance of the patent by the US authorities is binding and absured. An important milestone for the international marketing of products based on the patented device and a special extraction process has thus been reached.



The patent application relates to an innovative device and a method for the efficient, selective and gentle extraction of one or more components from biological materials, in particular cannabinoids such as the medically used CBD. The biological components obtained by the patented process can be processed accordingly and administered either via the medical inhaler or via the needleless syringe, depending on the medical indication.



Dr. Karsten Behlke, Managing Director of BG Braingate Technology: “The pending issuance of the US patent is an important milestone for our international protection strategy and the commercial exploitation of our technology in the fast-growing market for plant-based active substances.”



Dr. Gerald Schüssel, CEO of More Impact: “With the US patent granted in the near future, the high level of technological innovation in our portfolio companies is once again underpinned on an international scale.”



With the forthcoming patent grant, More Impact and Braingate Technology are expanding their leading technological position in the field of innovative extraction processes.



The forthcoming patent issuance complements the existing patent families and underpins the high-tech medical hub's claim to technological and innovative leadership.



About More Impact AG

More Impact AG is a listed high-tech medical hub that specializes in the development and support of innovative companies in the medical field. With a focus on securing patents and commercializing product innovations, More Impact contributes to making cutting-edge MedTech technologies accessible to a broad part of the population and sustainably improving global healthcare. Strategic acquisitions and divestitures of companies, divisions or individual patents round off the business model.



Contact – Investor & Media Relations

edicto GmbH

Axel Mühlhaus / Svenja Liebig

+49 69 90550 5-50

moreimpact@edicto.de



 





















15.04.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

























Language: English
Company: More Impact AG

Mörfelder Landstraße 277 b

60598 Frankfurt

Germany
Phone: +49 69 38076661
E-mail: info@moreimpactag.de
Internet: https://moreimpactag.de
ISIN: DE000A1PG979, DE000A40ZTM3
WKN: A1PG97
Listed: Regulated Unofficial Market in Dusseldorf
EQS News ID: 2118140





 
End of News EQS News Service





2118140  15.04.2025 CET/CEST



\"\"